Prothena Corp. Plc

As of October 3, 2025, Prothena Corp. Plc shows a mildly bullish trend overall, supported by mixed technical indicators, including a bullish monthly RSI and weekly MACD, but tempered by bearish daily moving averages.

As of October 3, 2025, Prothena Corp. Plc shows a mildly bullish technical trend, supported by strong short-term performance but tempered by mixed indicators and poor long-term returns.

As of October 3, 2025, Prothena Corp. Plc shows a mildly bullish technical trend, supported by positive MACD, RSI, and OBV signals, despite some bearish indicators in moving averages and Bollinger Bands, while it has outperformed the S&P 500 recently but underperformed over longer periods.

As of August 22, 2025, Prothena Corp. Plc is in a mildly bearish trend, with key indicators supporting this view, and has significantly underperformed the S&P 500 with a year-to-date return of -40.94%.

As of August 8, 2022, Prothena Corp. Plc is considered overvalued and risky due to a negative return on equity of -25.19%, a price to book value ratio of 0.67, and unfavorable comparisons to peers, indicating a cautious outlook on its financial health.

As of August 8, 2022, Prothena Corp. Plc is considered overvalued and risky due to unfavorable financial metrics, including a negative ROE of -25.19% and a year-to-date return of -56.25%, significantly underperforming the S&P 500.

As of June 6, 2025, Prothena Corp. Plc exhibits a bearish trend with strong downward pressure indicated by bearish MACD and moving averages, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of March 2022, Prothena Corp. Plc's management team includes Dr. Lars Ekman (Independent Chairman), Dr. Gene Kinney (President and CEO), and several independent directors: Ms. Paula Cobb, Mr. Richard Collier, Mr. Shane Cooke, Dr. K. Anders Harfstrand, and Dr. Christopher Henney. The team features a blend of executive leadership and independent directors.

Prothena Corp. Plc is a biotechnology company focused on developing immunotherapies for diseases related to protein misfolding and cell adhesion. As of March 2025, it has a market cap of $306.81 million, with net sales of $3 million and a net loss of $60 million.

As of Jun 18, Prothena Corp. Plc has a market capitalization of 306.81 million, with net sales of 137.93 million and a net profit of -110.27 million over the latest four quarters. The company reported shareholder's funds of 486.93 million and total assets of 547.11 million as of Dec 24.